-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in PureTech Health Plc (NASDAQ:PRTC) Drops By 89.4%
Short Interest in PureTech Health Plc (NASDAQ:PRTC) Drops By 89.4%
PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 500 shares, a drop of 89.4% from the August 15th total of 4,700 shares. Based on an average trading volume of 3,700 shares, the days-to-cover ratio is currently 0.1 days.
Institutional Trading of PureTech Health
An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. grew its position in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company's stock after buying an additional 630,000 shares during the period. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. 2.32% of the stock is currently owned by hedge funds and other institutional investors.
Get PureTech Health alerts:PureTech Health Price Performance
NASDAQ PRTC traded up $0.24 during mid-day trading on Thursday, reaching $29.29. 200 shares of the company's stock traded hands, compared to its average volume of 1,478. The company has a fifty day simple moving average of $27.09 and a 200-day simple moving average of $25.12. PureTech Health has a 1-year low of $18.15 and a 1-year high of $54.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.54 and a quick ratio of 2.22.
Wall Street Analyst Weigh In
PRTC has been the topic of a number of recent research reports. Piper Sandler boosted their target price on shares of PureTech Health from $37.00 to $44.00 and gave the stock an "overweight" rating in a research report on Thursday, August 25th. SVB Leerink cut their price objective on shares of PureTech Health from $70.00 to $66.00 and set an "outperform" rating on the stock in a report on Wednesday, June 15th.PureTech Health Company Profile
(Get Rating)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
Featured Articles
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Has 3M Reached the Point of Being so Bad It's Good?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 500 shares, a drop of 89.4% from the August 15th total of 4,700 shares. Based on an average trading volume of 3,700 shares, the days-to-cover ratio is currently 0.1 days.
PureTech Health Plc(納斯達克代碼:prtc-Get Rating)8月份空頭股數股價大幅下跌。截至8月31日,空頭股數共有500股,與8月15日的4700股相比,下降了89.4%。以3,700股的平均成交量計算,目前天數與回補比率為0.1天。
Institutional Trading of PureTech Health
PureTech Health的制度性交易
An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. grew its position in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company's stock after buying an additional 630,000 shares during the period. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. 2.32% of the stock is currently owned by hedge funds and other institutional investors.
一家機構投資者最近提高了對PureTech Health股票的頭寸。根據AWM Investment Company Inc.在提交給美國證券交易委員會的最新13F文件中的數據,第二季度該公司在PureTech Health Plc(納斯達克代碼:PRTC-GET評級)的股票持倉增加了2,100.0%。該基金持有66萬股該公司股票,在此期間又購買了63萬股。截至最近提交的美國證券交易委員會申請文件,AWM Investment Company Inc.持有PureTech Health約2.32%的股份,價值2,513,000美元。2.32%的股票目前由對衝基金和其他機構投資者持有。
PureTech Health Price Performance
PureTech健康性價比
NASDAQ PRTC traded up $0.24 during mid-day trading on Thursday, reaching $29.29. 200 shares of the company's stock traded hands, compared to its average volume of 1,478. The company has a fifty day simple moving average of $27.09 and a 200-day simple moving average of $25.12. PureTech Health has a 1-year low of $18.15 and a 1-year high of $54.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.54 and a quick ratio of 2.22.
納斯達克商城週四午盤交易中上漲0.24美元,至29.29美元。該公司有200股股票易手,而其平均成交量為1,478股。該公司的50日簡單移動均線切入位為27.09美元,200日簡單移動均線切入位為25.12美元。PureTech Health的一年低點為18.15美元,一年高位為54.39美元。該公司的債務權益比為0.02,流動比率為2.54,速動比率為2.22。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
PureTech Health Company Profile
PureTech Health公司簡介
(Get Rating)
(獲取評級)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
PureTech Health plc是一家臨牀階段的生物治療公司,在美國發現、開發和銷售治療炎症、纖維化和免疫、頑固性癌症、淋巴和胃腸道、神經和神經心理以及其他疾病的藥物。該公司提供靶向M膽鹼乙酰膽鹼受體的KarXT,用於治療阿爾茨海默病的精神分裂症和精神病;用於治療雄激素性脱髮、上皮老化和其他疾病的再生生物學平臺;用於治療慢性和急性炎症性疾病的免疫調節平臺;用於從人體微生物羣中分離出基於特定細菌羣的口服療法;以及用於治療與抑鬱症、多發性硬化症、COVID後和ICU以及癌症相關疾病相關的認知功能障礙的療法。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Has 3M Reached the Point of Being so Bad It's Good?
- 免費獲取StockNews.com關於PureTech Health(PRTC)的研究報告
- 為什麼醫療產品製造商Repligen可能成為潛在收購對象
- 在10%的水平上,Arbor Realty Trust的股息值得嗎?
- 投資者應關注RF Industries
- Netflix可能剛剛觸底的兩個原因
- 3M已經到了壞到好的地步了嗎?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
獲得PureTech HealthDaily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對PureTech Health和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧